

| Company Name:   | Sawai Pharmaceutical Co., Ltd.      |  |
|-----------------|-------------------------------------|--|
| Representative: | Kenzo Sawai                         |  |
| -               | President, Representative Director  |  |
|                 | (Code No.: 4555, TSE, 1st Section)  |  |
| Contact:        | Yasushi Kora                        |  |
|                 | General Manager, Public Relations & |  |
|                 | Investor Relations Office           |  |
|                 | (TEL: +81-6-6105-5823)              |  |

# Notice of Cancellation of Treasury Shares and Treasury Stock Acquisition Rights

Sawai Pharmaceutical Co., Ltd. (hereinafter referred to as "the **Company**") hereby announces that its Board of Directors has resolved at the meeting held today to cancel treasury shares in accordance with Article 178 of the Companies Act and to cancel treasury stock acquisition rights in accordance with Article 276 of the Companies Act.

### I. Cancellation of treasury shares

## (1) Reason for the cancellation of treasury shares

The Company is planning to incorporate a holding company (wholly owning parent company) called "SAWAI GROUP HOLDINGS Co., Ltd." (hereinafter referred to as the "Holding Company") through sole-share transfer by the Company (hereinafter referred to as the "Share Transfer") as on April 1, 2021. In accordance with the provisions of the Share Transfer Plan approved at the extraordinary general meeting of shareholders held on December 21, 2020, the Company will cancel all of the treasury shares held by the Company as of the point in time immediately preceding the acquisition of all of the issued and outstanding shares of the Company by the Holding Company (hereinafter referred to as the "Base Time").

### (2) Type of shares to be cancelled

Common stock of the Company

## (3) Number of shares to be cancelled

All of the treasury shares held by the Company as of the Base Time

### (4) Scheduled date of cancellation

March 31, 2021 (All of the treasury shares will be cancelled at the Base Time.)

(Reference)

| Expected status of treasury shares held as of March 31, 2021 |                   |
|--|-------------------|
| Total number of shares issued (excluding treasury shares)    | 43,791,339 shares |
| Number of treasury shares                                    | 299,649 shares    |

### **II**. Cancellation of treasury stock acquisition rights

(1) Reason for the cancellation of treasury stock acquisition rights

With respect to the 2nd Stock Acquisition Rights of the Company issued in accordance with the resolution of the Board of Directors dated June 25, 2015, the Company plans to acquire some of those stock acquisition rights without compensation due to the resignation of some of the right holders (including resignation to be made prior to the Base Time) and hold them as treasury stock acquisition rights in the name of the Company. In connection with the Share Transfer, the Company will cancel all of the treasury stock acquisition rights held by the Company as of the Base Time.

## (2) Name of stock acquisition rights to be cancelled

The 2nd Stock Acquisition Rights of the Company

- (3) Type of stock acquisition rights to be cancelled Common stock of the Company
- (4) Number of stock acquisition rights to be cancelled

All of the treasury stock acquisition rights held by the Company as of the Base Time

## (5) Scheduled date of cancellation

March 31, 2021 (All of the treasury stock acquisition rights will be cancelled at the Base Time.)

(Reference)

Expected status of treasury stock acquisition rights held as of March 31, 2021(100 shares per 1 (one) stock acquisition right)Total number of remaining stock acquisition rights(excluding treasury stock acquisition rights)Treasury stock acquisition rights247 stock acquisition rights

End.